Barclays’s Connect Biopharma Holdings CNTB Stock Holding History

Barclays’s Portfolio CNTB Stock Details CNTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-313,732	Closed	-$947K	–	5054
2022 Q1	$947K	Buy	+313,732	New	+$1.32M	﹤0.01%	2455

Other funds holding CNTB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Barclays's CNTB Position: Q2 2022 in Review

Barclays sold out of Connect Biopharma Holdings (CNTB) in Q2 2022, closing a stake of 313,732 shares — an estimated $947K sold.

Barclays first reported a position in CNTB in Q1 2022 and held it in 1 quarter. The position peaked at $947K in Q1 2022. 29 funds tracked by Wall St. Rank hold CNTB as of Q2 2022.

Barclays reported no remaining Connect Biopharma Holdings position as of Q2 2022 after selling out during the quarter.
Barclays sold 313,732 Connect Biopharma Holdings shares in Q2 2022, an estimated $947K.
Barclays first reported a position in Connect Biopharma Holdings in Q1 2022 and held it in 1 quarter.
Barclays's Connect Biopharma Holdings position peaked at $947K in Q1 2022.
29 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.